عنوان
پدید آورنده
موضوع
رده
کتابخانه
محل استقرار
INTERNATIONAL STANDARD BOOK NUMBER
(Number (ISBN
1782622535
(Number (ISBN
1782627510
(Number (ISBN
1849739471
(Number (ISBN
9781782622536
(Number (ISBN
9781782627517
(Number (ISBN
9781849739474
Erroneous ISBN
1849739471
Erroneous ISBN
9781849739474
NATIONAL BIBLIOGRAPHY NUMBER
Number
b399197
TITLE AND STATEMENT OF RESPONSIBILITY
Title Proper
Nanomedicines
General Material Designation
[Book]
Other Title Information
design, delivery and detection /
First Statement of Responsibility
editor: Martin Braddock.
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
1 online resource.
SERIES
Series Title
RSC drug discovery ;
Volume Designation
51
GENERAL NOTES
Text of Note
Includes index.
CONTENTS NOTE
Text of Note
Cover; Contents; Preface; Chapter 1 Design Considerations for Properties of Nanocarriers on Disposition and Efficiency of Drug and Gene Delivery; Chapter 2 Targeting Cyclins and Cyclin-dependent Kinases Involved in Cell Cycle Regulation by RNAi as a Potential Cancer Therapy; Chapter 3 Nanoparticle Carriers to Overcome Biological Barriers to siRNA Delivery; Chapter 4 Magnetic Targeting as a Vehicle for the Delivery of Nanomedicines; Chapter 5 The Development of Theranostics -- Imaging Considerations and Targeted Drug Delivery
Text of Note
4.2 External Magnetic Device4.3 Labeling Mesenchymal Stem Cells with Supraparamagnetic Iron Oxide; 4.4 Adhesion of m-MSCs to the Tissue Injured Site; 4.5 Animal Studies; 4.6 Conclusion; Acknowledgments; References; 5.1 Introduction; 5.2 Theranostic Carrier Materials; 5.3 Theranostics and Imaging; 5.4 Conclusions; References; 6.1 Introduction; 6.2 Imaging for In vivo Evaluation of the Spatio-temporal Distribution Characteristics of Nanomedicines; 6.3 Use of Imaging to Understand and Optimize Nanomedicine Performance; 6.4 Clinical Experience and Future Considerations; References
Text of Note
7.1 Introduction7.2 Anticancer Agents Incorporating Micelles under Clinical Evaluation; 7.3 Verification of the EPR Effect using Imaging Mass Spectrometry; 7.4 Discussion and Conclusion; References; 8.1 Introduction; 8.2 Topoisomerase 1 Inhibitors; 8.3 Hypoxia Inducible Factor-1 Inhibitors; 8.4 Cancer Stem Cells; 8.5 Combination Therapy; 8.6 CRLX101; 8.7 Conclusion; References; 9.1 Introduction; 9.2 Nanocarriers for Drug Delivery to Solid Tumors; 9.3 Doxil®-The First FDA-approved Nano-drug; 9.4 Taxane-based Nanodelivery (Abraxane® and Genexol-PM®); 9.5 CrEL-free Formulations of PTX
Text of Note
Chapter 13 Doxil® -- the First FDA-approved Nano-drug: from Basics via CMC, Cell Culture and Animal Studies to Clinical UseSubject Index; References; 1.1 Introduction; 1.2 Types of Nanocarriers/Nanoparticles; 1.3 Physicochemical Factors that Affect Nanoparticle Efficiency; 1.4 Conclusions; References; 2.1 Introduction; 2.2 The Cell Cycle; 2.3 Deregulation of the Cell Cycle in Cancer; 2.4 RNA Interference; 2.5 Concluding Remarks; Acknowledgments; References; 3.1 Introduction; 3.2 Extracellular Barriers; 3.3 Cellular Barriers; 3.4 siRNA Delivery Systems; References; 4.1 Introduction
Text of Note
Chapter 6 The Role of Imaging in Nanomedicine Development and Clinical TranslationChapter 7 Anticancer Agent-Incorporating Polymeric Micelles: from Bench to Bedside; Chapter 8 Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101; Chapter 9 Nanodelivery Strategies in Breast Cancer Chemotherapy; Chapter 10 Developing a Predictable Regulatory Path for Nanomedicines by Accurate and Objective Particle Measurement; Chapter 11 Nanomedicine: Promises and Challenges; Chapter 12 The Challenge of Regulating Nanomedicine: Key Issues
0
8
8
8
8
SUMMARY OR ABSTRACT
Text of Note
Nanomedicines and nanopharmacology is a rapidly developing and evolving field with new techniques and applications under constant development. This book will provide an overview of the chemistry of nanocarrier design and the considerations that need to be made when developing a nanomedicine. Providing an understanding of the relationship of nanocarrier, drug and targetting moieties and physico-chemical properties, this title will provide an accurate and current representation of the field by addressing the promises, prospects and pitfalls of nanomedicine. Covering a wide range of areas in detail, this book will provide an excellent companion for medicinal chemists, pharmacologists and biochemists working in industry or academia.
OTHER EDITION IN ANOTHER MEDIUM
Title
Nanomedicines.
International Standard Book Number
9781849739474
TOPICAL NAME USED AS SUBJECT
Nanomedicine.
Nanoparticles.
HEALTH & FITNESS-- Holism.
HEALTH & FITNESS-- Reference.
MEDICAL-- Alternative Medicine.
MEDICAL-- Atlases.
MEDICAL-- Essays.
MEDICAL-- Family & General Practice.
MEDICAL-- Holistic Medicine.
MEDICAL-- Osteopathy.
Nanomedicine.
Nanoparticles.
PERSONAL NAME - ALTERNATIVE RESPONSIBILITY
Braddock, Martin
CORPORATE BODY NAME - ALTERNATIVE RESPONSIBILITY
Royal Society of Chemistry (Great Britain)
ORIGINATING SOURCE
Date of Transaction
20170210095900.0
Cataloguing Rules (Descriptive Conventions))
pn
ELECTRONIC LOCATION AND ACCESS
Electronic name
مطالعه متن کتاب [Book]
Y
